Navigation Links
Catabasis Closes $32.4 Million Series B Financing
Date:11/14/2013

CAMBRIDGE, Mass., Nov. 15, 2013 /PRNewswire/ -- Catabasis Pharmaceuticals, Inc., today announced it has completed a $32.4 million Series B financing round led by new investor Lightstone Ventures. A leading public crossover fund and all current Catabasis investors, including SV Life Sciences, Clarus Ventures, MedImmune Ventures and Advanced Technology Ventures, also participated in the financing.

"This investment reflects our confidence in Catabasis' pipeline of SMART Linker conjugates as much as our belief in management's ability to successfully advance its clinical candidates," said Jean George, partner of Lightstone Ventures. "Catabasis has achieved a number of important milestones in the past year including positive data from Phase 1 studies of both CAT-2003 and CAT-1004. We look forward to working with the management team as they complete the ongoing Phase 2 trial for CAT-2003 and seek to advance the rest of the pipeline."

Catabasis plans to use proceeds from this financing to support the development of its lead compound, CAT-2003, a modulator of the lipid synthesis pathway, which is currently in a Phase 2 clinical trial in patients with hypertriglyceridemia and in combination with statins in patients with hypercholesterolemia. Catabasis also plans to use the proceeds to support the continued clinical and pre-clinical development of other SMART Linker conjugates in the pipeline.

"We are tremendously excited about the progress we've made with our pipeline thus far, having reported positive Phase 1 data for both CAT-2003 and CAT-1004 and having advanced CAT-2003 to Phase 2," said Jill Milne, Ph.D., co-founder and chief executive officer of Catabasis. "This financing enables Catabasis to continue to execute on the promise of its pipeline for dyslipidemias and diseases involving chronic inflammation."  '/>"/>

SOURCE Catabasis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Catabasis Initiates Phase 1 Trial of CAT-2003 for Treatment of Severe Hypertriglyceridemia
2. Catabasis Pharmaceuticals Announces Issuance of Patents for CAT-1000 and CAT-2000 Series
3. Catabasis Names Ian Sanderson Chief Financial Officer
4. Independa Closes Convertible Note Funding at $2.35 Million
5. Stereotaxis Closes $18.5 Million Private Placement Financings
6. Boston Scientific Closes Cameron Health Acquisition
7. C8 MediSensors Closes $19 million Preferred Stock Financing
8. Igenica Closes $33 Million in Series C Funding
9. BONESUPPORT Closes Second Tranche of Funding
10. PTC Therapeutics Closes $30 Million Financing
11. Chiasma Closes $38.5 Million Equity Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014 PuraMed BioScience ® ... of over-the-counter (OTC) medicinal and healthcare products, announced ... M name along with the name,s red and ... the trademarked name MigraPure ®  going forward. ... PuraMed,s homeopathic, natural migraine pain reliever will be ...
(Date:7/30/2014)... 30, 2014  El Camino Hospital, a leader in ... utilizing the Leaf Patient Monitoring system to help prevent ... of patients susceptible to bed sores. The ... study of the system, which showed dramatic improvement in ... regularly is the one of the most effect ways ...
(Date:7/30/2014)... July 30, 2014  InnoPharma, Inc. today announced the ... generic equivalent of Zyprexa® injection), in Canada.  Olanzapine is ... behaviors in patients with schizophrenia or bipolar I mania. ... drug, InnoPharma has entered into an agreement with Sandoz ... will make, use, sell, market and distribute Olanzapine Injection ...
Breaking Medicine Technology:PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 2PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 3El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 2El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 3InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2
(Date:7/30/2014)... Alan Mozes HealthDay Reporter ... want to help their preschooler shed excess pounds may want ... Youngsters whose parents joined them in a supervised behavioral modification ... in a traditional child-only program (an average difference of about ... losing almost 15 pounds over two years, according to the ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 The family ... bleeding has filed a Xarelto lawsuit ( http://www.xareltolawsuitcenter.com/ ... thinner, Bernstein Liebhard LLP reports. According to the complaint, ... District of Vermont on July 25th, the decedent had ... suffered an irreversible brain bleed that ultimately led to ...
(Date:7/30/2014)... 2014) The phrase "we caught it early" is possibly ... midst of a cancer diagnosis. Combating cancer in its ... certain part of the body, gives patients the best ... colon, prostate and other forms of cancer are touted ... providers recommend cancer screenings as a precautionary measure, especially ...
(Date:7/30/2014)... McLean, VA (PRWEB) July 30, 2014 ... its 2014-2015 Board of Directors. Sandra Aiken Chack will ... this month at the EDNF 2014 Annual Learning Conference ... National Foundation has an ambitious agenda ahead of us. ... Clinical Care & Research at the Greater Baltimore Medical ...
(Date:7/30/2014)... Children’s Hospital of Michigan Foundation and ... 4 p.m. to 7 p.m. Wednesday, August 6 at ... Livonia, MI 48152). The event will feature Detroit Red ... music, snacks and local public safety officials. Kohl’s will ... of Michigan Foundation. , The gift supports Kohl’s ...
Breaking Medicine News(10 mins):Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 2Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 3Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 4Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 3Health News:Ehlers-Danlos National Foundation Announces New Leadership 2Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 2Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 3Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 4
... Paralleling the nation,s efforts to find ways to expand ... care, Concierge Choice Physicians (CCP) announced in ... physicians care for more than 250,000 patients in 12 states - ... Pioneering the concept of hybrid concierge medicine, CCP offers primary care ...
... EAST HAMPTON, N.Y., July 8 The Max Cure Foundation ... cancer causes -- announced today its first charity benefit, the ... day, to take place on Saturday, August 22, from 2:00 ... grounds of the East Hampton Indoor Tennis Club, 175 Daniels ...
... 8 Insulet Corporation (Nasdaq: PODD ), ... that the Company is introducing an environmentally friendly disposal ... Eco-Pod program will reduce the impact of used Pods ... landfills. It is the industry,s first program for ...
... the most famous hotels in Coconut Grove, Florida is now offering ... , In the spirit of game shows of yesterday and today, ... Deal special. It,s simple...call the hotel, mention the Let,s Make a ... suites...the hotel may counter with a Deal or No Deal offer, ...
... July 8 Stereotaxis, Inc. (Nasdaq: STXS ) announced ... quarter ended June 30, 2009, on Thursday, August 6, ... a conference call and webcast on Thursday, August 6, ... Company,s second quarter results and current corporate developments. The dial-in number ...
... July 8 You,ve just waited through the longest two minutes ... to be positive. After catching your breath, you realize the only ... same again. That,s because you,ve just learned you,re pregnant! This discovery ... mind, and you know you need fast answers. That,s when you ...
Cached Medicine News:Health News:Hybrid Concierge Medical Practice Provides More Value, Options to Growing Number of Physicians Nationwide 2Health News:Hybrid Concierge Medical Practice Provides More Value, Options to Growing Number of Physicians Nationwide 3Health News:The Max Cure Foundation Announces Its First Charity Benefit: The 'Roar for a Cure' Carnival to Be Held on Saturday, August 22, 2009 2Health News:The Max Cure Foundation Announces Its First Charity Benefit: The 'Roar for a Cure' Carnival to Be Held on Saturday, August 22, 2009 3Health News:The Max Cure Foundation Announces Its First Charity Benefit: The 'Roar for a Cure' Carnival to Be Held on Saturday, August 22, 2009 4Health News:The Max Cure Foundation Announces Its First Charity Benefit: The 'Roar for a Cure' Carnival to Be Held on Saturday, August 22, 2009 5Health News:Insulet Establishes Eco-Friendly Disposal Program for the OmniPod(R) Insulin Management System 2Health News:A Unique Rhythm In The Heart Of Coconut Grove, Florida 2Health News:Stereotaxis Announces Second Quarter 2009 Earnings Release Date and Conference Call 2Health News:A Bundle of Joy Brings a Bundle of Questions - Life123.com Delivers the Answers! 2
AST (SGOT) R1 + R2. Automated analyzer test kits....
For the quantitative determination of aspartate aminotransferase (AST) in human serum. The reagents are used in routine examination and monitoring of therapy and relapses....
Intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma. Reaction: Kinetic. Wavelength: 340 nm. Linearity: 268 U/L at 30C. Two vials, dry powder reagents...
Intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma. Reaction: Kinetic. Wavelength: 340 nm. Linearity: 440 U/L at 30C. Single vial, dry powder reagen...
Medicine Products: